New hope for Hard-to-Treat vasculitis: IL-2 shows promise
NCT ID NCT00574652
First seen Apr 26, 2026 · Last updated May 25, 2026 · Updated 6 times
Summary
This study tested a low dose of interleukin-2 (IL-2) in 10 people with hepatitis C-related vasculitis that did not improve with standard treatments. The goal was to see if IL-2 could boost regulatory T cells to calm the immune system and reduce inflammation. Researchers monitored immune responses, safety, and whether symptoms improved during and after therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRYOGLOBULINEMIA VASCULITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hôpital de la Pitié
Paris, 75651, France
Conditions
Explore the condition pages connected to this study.